Overview

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-09

Target enrollment:

Participant gender:

Summary

Currently, there are no standard treatment and relevant exploration for solid tumors patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment ofadvanced solid tumors with NED, in order to provide a new treatment option for advanced solid tumors patients with NED.

Phase:

PHASE2

Details

Lead Sponsor:

RenJi Hospital

Treatments:

surufatinib